| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 12:53:47 UTC |
|---|
| Update Date | 2021-09-26 23:07:38 UTC |
|---|
| HMDB ID | HMDB0253981 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Laquinimod |
|---|
| Description | Laquinimod belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group. Laquinimod is an extremely weak basic (essentially neutral) compound (based on its pKa). However, the response to a given dose was discrepant between both studies. Phase III studies for MS started in December 2007. On May 7, 2013 laquinimod was approved by the Russian Ministry of Health (the FDA analog) as a treatment for relapsing-remitting multiple sclerosis (RRMS) under the brand name Nerventra. The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in MS among patients beyond a placebo. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis. Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. This compound has been identified in human blood as reported by (PMID: 31557052 ). Laquinimod is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Laquinimod is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1 InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Laquinimod | MeSH |
|
|---|
| Chemical Formula | C19H17ClN2O3 |
|---|
| Average Molecular Weight | 356.81 |
|---|
| Monoisotopic Molecular Weight | 356.0927701 |
|---|
| IUPAC Name | 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide |
|---|
| Traditional Name | laquinimod |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3 |
|---|
| InChI Key | GKWPCEFFIHSJOE-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Anilides |
|---|
| Direct Parent | Aromatic anilides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Aromatic anilide
- Quinoline-3-carboxamide
- Haloquinoline
- Dihydroquinolone
- Hydroxyquinoline
- Chloroquinoline
- Dihydroquinoline
- Quinoline
- Pyridine carboxylic acid or derivatives
- Hydroxypyridine
- Pyridinone
- Aryl chloride
- Aryl halide
- Pyridine
- Heteroaromatic compound
- Vinylogous amide
- Tertiary carboxylic acid amide
- Vinylogous acid
- Lactam
- Carboxamide group
- Azacycle
- Carboxylic acid derivative
- Organoheterocyclic compound
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 18.8666 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.39 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3064.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 560.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 211.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 308.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 225.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 785.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 818.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 96.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1676.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 614.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1816.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 557.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 521.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 466.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 235.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Laquinimod GC-MS (Non-derivatized) - 70eV, Positive | splash10-002u-4769000000-ba48e04fdbcae687b02d | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Laquinimod GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Laquinimod GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Laquinimod GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-04 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 10V, Positive-QTOF | splash10-0a4i-0019000000-6da9532401f720034532 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 20V, Positive-QTOF | splash10-052r-0196000000-6b66e60245cd26bd71df | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 40V, Positive-QTOF | splash10-052r-2980000000-d71fda13dfd6db23a46a | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 10V, Negative-QTOF | splash10-0a4i-0059000000-a5394a4f4836947e9019 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 20V, Negative-QTOF | splash10-0a4i-1395000000-d1da2ec9b5ba36212fd0 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 40V, Negative-QTOF | splash10-0c00-2910000000-3a625d8bae29b8d0d176 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 10V, Positive-QTOF | splash10-0a4r-0059000000-320c8fba478e8dc8a1b2 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 20V, Positive-QTOF | splash10-000i-0194000000-e98d561a2b084be50b83 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 40V, Positive-QTOF | splash10-000i-1390000000-5aba097cf2b15d51f404 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 10V, Negative-QTOF | splash10-0a4i-0009000000-f281a2e503abace86d62 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 20V, Negative-QTOF | splash10-0a4i-3295000000-9db6a44f01c32b259f4e | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Laquinimod 40V, Negative-QTOF | splash10-001l-9312000000-35292d9dfbd3df1cdfaf | 2021-10-12 | Wishart Lab | View Spectrum |
|
|---|